This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Charles River Laboratories (CRL) Is Up 2.99% in One Week: What You Should Know
by Zacks Equity Research
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
by Zacks Equity Research
Zacks.com featured highlights include: Cadence Design, LPL, Charles and Automatic Data
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Top Ranked Growth Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 2nd
Charles River (CRL) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Encouraging Near-Term Outlook for Medical Services Industry
by Urmimala Biswas
With growing importance of effective healthcare management, the medical service industry is becoming an integral part of the modern healthcare mechanism.
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Motors, Charles River, DSW, Shoe Carnival and Boingo
US Economy Had a Banner 2018: Top 5 Gainers
by Tirthankar Chakraborty
The U.S. GDP grew 2.9% in 2018, matching 2015 as the biggest increase since the 2007-2009 Great Recession.
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
4 Drug Stocks to Buy Despite Price Hearing Woes
by Nitish Marwah
A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.